Jan Rosier

Professor Rosier holds both a Doctorate in Pharmaceutical Sciences (Ghent University, Belgium) and a Doctorate in Management (Cranfield School of Management, UK). He was a Fulbright Scholar at Harvard University and was awarded a NATO research fellowship for research at MIT, Cambridge. As vice president pharmaceutical drug development at Johnson & Johnson he was instrumental in the development of TIBOZOLE®, LIVOSTIN®, PREPULSID®, SPORANOX®, RISPERDAL® and ERGAMISOL® and was awarded the Johnson & Johnson Leadership Award for outstanding and exceptional contribution to the development of PREZISTA® and INTELENCE® for the treatment of AIDS. In 2009, he became Chief Executive Officer of FORMAC Pharmaceuticals NV, a high technology drug delivery spin-off from the University of Leuven that uses silica based technology to increase the performance of drugs. Jan has extensive experience in attracting venture capital for high-risk academic spin-off biotech firms. His career has continuously taken place at the interface between university and industry. During his stay in industry he was engaged in academic biomedical research which resulted in scientific papers published in e.g. the International Journal of Pharmaceutics, European Journal of Biopharmaceutics, Electrophoresis, Journal of Chromatography Biomedical Applications, Nature etc. Since 2008, he teaches new drug development at the University of Leuven as a visiting professor. He also researches innovation in biotech firms as a Visiting Fellow at the Cranfield School of Management (UK). Jan is author of 'Global New Drug Development - An Introduction' (Wiley-Blackwell) and is currently writing his new book on the business of biotechnology. He is also a member of the Advisory Board of Incentives for Global Health's Health Impact Fund (healthimpactfund.org).